<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804947</url>
  </required_header>
  <id_info>
    <org_study_id>BuMel-MM</org_study_id>
    <nct_id>NCT00804947</nct_id>
  </id_info>
  <brief_title>Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen</brief_title>
  <official_title>Ensayo Fase II de Trasplante autólogo de Sangre periférica en Pacientes Con Mieloma múltiple Tras Acondicionamiento Con Busulfan Intravenoso y Melfalan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Para La Investigacion Hospital La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Para La Investigacion Hospital La Fe</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen
      for patients with Multiple Myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Efficacy and safety of the procedure in terms of number of remissions, survival,
      event-free survival, relapse risk, and early transplant-related mortality (up to day +100).

      Secondary Graft kinetics (time to neutrophil and platelet recovery after ASCT) 2.Analyze the
      presence of transplant-related complications (infections, sinusoidal occlusive syndrome and
      others) 3.Analyze prognostic factors for engraftment, remission rate, relapse risk,
      disease-free and overall survival after ASCT
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to analyze the safety profile and determine the overall response rate after ASCT with this conditioning regimen.</measure>
    <time_frame>Within the first three months after transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the complete response (CR) rate, the duration of the response, time to progression, event-free and overall survival</measure>
    <time_frame>Up to 5 years after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Intravenous busulfan and melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous busulfan and melphalan</intervention_name>
    <description>BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.</description>
    <arm_group_label>Intravenous busulfan and melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic multiple myeloma

          -  Male or female subject age &gt;= 70 years

          -  The subject has received at least one previous line of therapy including:

          -  Front-line treatment with VBMCP/VBAD or VAD or second-line therapy with regimens
             including bortezomib, thalidomide or lenalidomide

          -  The subject has given voluntary written informed consent

        Exclusion Criteria:

          -  Use of bortezomib, thalidomide or lenalidomide as front-line therapy

          -  ECOG satus &gt;=2

          -  Left ventricular ejection fraction &lt;40%

          -  DLCO and FVC &lt;39% theoretical value

          -  Abnormal liver function(total bilirubin &gt; 2 mg/dL and/or ALT or AST &gt; 3 x ULN)

          -  Serum creatinine at transplant &gt;1.6 mg/dL and/or creatinine clearance &lt; 65 mL/minute

          -  Subject has an active systemic infection requiring treatment

          -  Subject had a myocardial infarction within 6 months of enrollment or has NYHA Class
             III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular
             arrythmias

          -  Subject has any other serious medical condition (severe hepatic impairment,
             pericardial disease, acute diffuse infiltrative pulmonary disease) or psychiatric
             illness that could potentially interfere with the completion of treatment of this
             protocol

          -  Subject is known to be immunodeficiency virus (HIV)-positive

          -  Subject has received an experimental drug or used and experimental medical device
             within 4 weeks before enrollment

          -  If female, the subject is pregnant or breast-feeding. Confirmation that the subject is
             not pregnant must be established by a negative pregnancy test at screening. Pregnancy
             testing is not required for postmenopausal or surgically sterilized women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel A Sanz, MD</last_name>
    <role>Study Director</role>
    <affiliation>S: de Hematología. Hospital La Fe, Valencia. Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier de la Rubia, MD</last_name>
    <phone>34963862746</phone>
    <email>delarubia_jav@gva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillermo Sanz, MD</last_name>
    <phone>34963862746</phone>
    <email>sanz_gui@gva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Insular Canarias</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan D González, MD</last_name>
      <email>jdgonsan@gobiernodecanarias.org</email>
    </contact>
    <investigator>
      <last_name>Juan D González, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrián Alegre, MD</last_name>
      <email>Adrian.Alegre@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Adrián Alegre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan J Lahuerta, MD</last_name>
      <email>jjlahuerta@terra.es</email>
    </contact>
    <investigator>
      <last_name>Juan J Lahuerta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. de Hematología. Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier de la Rubia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo Sanz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isidro Jarque, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Solano, MD</last_name>
      <email>carlos.solano@uv.es</email>
    </contact>
    <investigator>
      <last_name>Carlos Solano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paz Ribas, MD</last_name>
      <email>ribas_paz@gva.es</email>
    </contact>
    <investigator>
      <last_name>Paz Ribas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>December 8, 2008</last_update_submitted>
  <last_update_submitted_qc>December 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Javier de la Rubia</name_title>
    <organization>Hematology Service. Hospital La Fe. Valencia, Spain</organization>
  </responsible_party>
  <keyword>Autologous transplantation</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Intravenous Busulfan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

